CN1823787A - Application of lucid ganoderma acid in preparation of cancer transfer inhibitor - Google Patents
Application of lucid ganoderma acid in preparation of cancer transfer inhibitor Download PDFInfo
- Publication number
- CN1823787A CN1823787A CN 200510112303 CN200510112303A CN1823787A CN 1823787 A CN1823787 A CN 1823787A CN 200510112303 CN200510112303 CN 200510112303 CN 200510112303 A CN200510112303 A CN 200510112303A CN 1823787 A CN1823787 A CN 1823787A
- Authority
- CN
- China
- Prior art keywords
- ganoderic acid
- acid
- tumor
- ganoderic
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An application of the ganoderic acid T and ganoderic acid Me in preparing the depressant for suppressing the both reproduction and transfer of cancer cells is disclosed.
Description
Technical field
The present invention relates to a kind of new purposes of Ganodenic acid, relate in particular to Ganoderic acid Me GA-Me (+)-Ganoderic acid Me (Ganoderic acidMe) and Ganoderic acid T GA-T Ganoderic acid T. (the Ganoderic acid T) application in the preparation cancer transfer inhibitor.
Background technology
The infiltration metastasis of cancerous cell is to cause cancer patient's main causes of death, also is that malignant tumor is different from carcinoid important symbol, also is simultaneously the key factor of decision tumor patient prognosis.The transfer that suppresses tumor cell is the important component part of antineoplaston.The medicine that the exploitation antitumor cell shifts to prolong patient life cycle, improve the quality of living significant.The infiltration metastasis of cancerous cell is an extremely complex dynamic process, and in transfer process, the locomotivity of cancerous cell self plays a major role.Therefore, the transfer of inhibition tumor cell is the important component part of exploitation antineoplaston medicine.
Ganoderma (Ganoderma lucidum) is Basidiomycetes, Polyporaceae, Ganoderma fungus, is exactly the famous and precious medicinal fungi of China since ancient times, has antitumor, reduces drug effects such as cholesterol level, anti-inflammatory in the blood.Modern medicine study finds that the major physiological active component is ganoderan and Ganodenic acid in the Ganoderma.Ganodenic acid (Ganodenic acid) is a kind of triterpene substance, has stronger pharmacologically active.The Ganodenic acid that has been separated in the various Ganodermas has reached kind more than 100, many its effective efficiencies of not identifying as yet at present.
Summary of the invention
The technical issues that need to address of the present invention are the application in the preparation cancer transfer inhibitor of open Ganodenic acid, to satisfy the needs of clinical practice.
The said Ganodenic acid of the present invention is Ganoderic acid Me GA-Me (+)-Ganoderic acid Me (Ganoderic acid Me, abbreviation GA-Me) or Ganoderic acid T GA-T Ganoderic acid T. (Ganoderic acid T, abbreviation GA-T).
The inventor finds that purification obtains Ganoderic acid T GA-T Ganoderic acid T. and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me in the Ganoderma fermented product extract, and low dose of i.e. generation suppresses the effect of tumor cell transfer and has dose dependent.Therefore they medicines as the treatment neoplasm metastasis can be applied in the chemotherapy of tumor.
Said low dose refers to the dosage that is lower than 1～10mg/ (kg body weight sky), and said heavy dose refers to the dosage that is higher than 10～100mg/ (kg body weight sky).
The invention still further relates to a kind of compositions, comprise sesame acid Me or the Ganoderic acid T GA-T Ganoderic acid T. and the pharmaceutically acceptable carrier for the treatment of effective dose.
Can put on the patient who needs treatment with Ganoderic acid Me GA-Me (+)-Ganoderic acid Me or Ganoderic acid T GA-T Ganoderic acid T. and pharmaceutically acceptable carrier with the form of compositions, general dosage is 1～100mg/ (kg body weight sky), specifically can change according to patient's age, the state of an illness etc.
Said carrier is meant the pharmaceutical carrier of pharmaceutical field routine, as diluent, excipient such as water etc., and filler, as starch, sucrose etc., binding agent, as cellulose derivative gelatin, polyvinylpyrrolidone etc., lubricant is as Pulvis Talci etc.Cancerometastasis inhibiting substances of the present invention can cooperate with the auxiliary material that does not influence pharmacotoxicological effect usually as dosage form and to make per os and para-oral preparation.
The compositions that Ganoderic acid Me GA-Me (+)-Ganoderic acid Me of the present invention or Ganoderic acid T GA-T Ganoderic acid T. and above-mentioned carrier constitute can put on the patient who needs this treatment by oral, snuffing, intravenous injection or hypodermic form.
Be used for when oral, its preparation can be become conventional tablet, powder or oral liquid;
When being used to inject, it can be adopted the method for this area routine, preparation becomes injection;
The various preparations of Ganoderic acid Me GA-Me (+)-Ganoderic acid Me of the present invention or Ganoderic acid T GA-T Ganoderic acid T. comprise powder, pill, and tablet, solid type preparation such as capsule, ointment sticks agent, and injections etc. can adopt the method for pharmaceutical field routine to be prepared;
In the preparation, the weight content of Ganoderic acid Me GA-Me (+)-Ganoderic acid Me or Ganoderic acid T GA-T Ganoderic acid T. is 0.1～99.9%, and preferred content is 0.5～99.9%.
Neoplasm metastasis medicine Ganoderic acid T GA-T Ganoderic acid T. provided by the invention and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me, has the effect that tumor cell shifts that suppresses under the low concentration situation, and this moment is not strong for Normocellular toxic action, thereby can bring into play the effect of further treating neoplasm metastasis more.Said low concentration refers to the dosage that is lower than 1～10mg/ (kg body weight sky).
Said Ganoderic acid Me GA-Me (+)-Ganoderic acid Me (GA-Me) or Ganoderic acid T GA-T Ganoderic acid T. (GA-T) can adopt document (Chem.Pharm.Bull., 34 (5), 2282-2285,1986 respectively by extracting in the glossy ganoderma mycelium fermentation; Agric.Biol.Chem., 51 (2), 619-622,1987) disclosed technology is prepared extraction, purity is greater than 99%, its separated at first evaluation in nineteen eighty-three (Tetrahedron Lett., 24 (10), 1081-1084,1983) and (Agric.Biol.Chem. in 1987,51 (2), 619-622,1987).
Cancerometastasis of the present invention presses down material, and low toxicity is suitable for people and mammal per os and non-oral administration.
Neoplasm metastasis medicine Ganoderic acid T GA-T Ganoderic acid T. provided by the invention and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me are compared with traditional Ganoderma, because effective ingredient is clear and definite, pharmacological effect is more targeted.
Said tumor is medically affiliated all kinds of tumors, comprises benign tumor and malignant tumor.And said malignant tumor comprises: malignant melanoma, malignant lymphoma, Alimentary tumor (gastric cancer, intestinal cancer, hepatocarcinoma, carcinoma of gallbladder, cancer of bile ducts, cancer of pancreas), pulmonary carcinoma, breast carcinoma, carcinoma of testis, ovarian cancer, uterus carcinoma, carcinoma of prostate, maxillary cancer, carcinoma of tongue, oral cancer, laryngocarcinoma, thyroid carcinoma, brain tumor, each sarcoid, osteosarcoma, leukemia, nervous system neoplasms, tumor of bladder, skin carcinoma, skin accessory organ's cancer and metastatic carcinoma of skin.
Animal experiment proves, cancer transfer inhibitor of the present invention, and low toxicity is suitable for people and mammal per os or non-oral administration.
Significant advantage of the present invention and technical progress:
Cancer transfer inhibitor Ganoderic acid T GA-T Ganoderic acid T. of the present invention and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me can both effectively influence the infiltration metastasis ability of tumor in vitro and in vivo in the experiment.
Cancer transfer inhibitor Ganoderic acid T GA-T Ganoderic acid T. of the present invention and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me are that the pure product that obtain are separated by high performance liquid chromatography in Ganoderma fermentation back, compare with the initial fermentation product, and its chemical property is more stable, and specific aim is also stronger simultaneously.
Description of drawings
Fig. 1 is the influence of Ganodenic acid to the tumor cell survival rate.
Fig. 2 is the influence of Ganodenic acid to the tumor cell locomotivity.
Fig. 3 is the influence of Ganodenic acid to the tumor cell adhesion ability.
Fig. 4 is a Ganodenic acid to the heavy suppression ratio of the tumor of tumor-bearing mice (x ± s).
Fig. 5 is Ganoderic acid Me GA-Me (+)-Ganoderic acid Me and Ganoderic acid T GA-T Ganoderic acid T. to Lewis lung cancer mouse lung metastasis inhibition effect (x ± s).
Fig. 6 be GA-Me and GA-T to KB, the toxic action of HeLa and 95-D tumor cell and HLF human normal cell line.
In the accompanying drawing, unless otherwise indicated, 1 is Ganoderic acid Me GA-Me (+)-Ganoderic acid Me, and 2 is Ganoderic acid T GA-T Ganoderic acid T..
The specific embodiment
The test that Ganoderic acid T GA-T Ganoderic acid T. and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me cell growth suppress:
To contain the Ganoderic acid T GA-T Ganoderic acid T. of variable concentrations and the culture fluid solution adding of Ganoderic acid Me GA-Me (+)-Ganoderic acid Me is connected in 96 orifice plates of same cell amount in advance, continuous culture 24h in incubator, investigate the survival rate of cell with mtt assay, study Ganoderic acid T GA-T Ganoderic acid T. and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me power thus for various cell killing effects, and the concentration (IC50) when measuring Ganoderic acid T GA-T Ganoderic acid T. and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me pair cell survival rate and producing half and suppress.
Tumor cell: 95D (the high transitivity lung carcinoma cell of people)
As can be seen from Figure 1, after the culture fluid through containing Ganoderic acid T GA-T Ganoderic acid T. and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me was cultivated 24h, the survival rate of each tumor cell obviously descended, and dose-effect relationship is bright.Pass through more as can be seen, the IC50=24.2 μ M of Ganoderic acid T GA-T Ganoderic acid T., and the IC50=58.4 μ M of Ganoderic acid Me GA-Me (+)-Ganoderic acid Me all can effectively suppress the growth of 95D.
Ganoderic acid T GA-T Ganoderic acid T. and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me are to the inhibition test of cancer cell metastasis ability
The tumor cell inoculation that will be in exponential phase is in 24 well culture plates, after cultivation treats that cell grows up to monolithic, make cut one, behind eyepiece micrometer measurement cut width, every hole adds two fun gi polysaccharides handles, parallel 4 holes of every concentration, and matched group adds the culture fluid of equivalent volumes, after hatching 24 hours, measure the cut width with eyepiece micrometer.The experiment triplicate is averaged.
Cut width after cut width-drug treating before the distance=drug treating of cell migration migration
The result as shown in Figure 2, along with the increase of Ganodenic acid concentration, the locomotivity of tumor cell is suppressed gradually.Ganoderic acid T GA-T Ganoderic acid T. is 10.97 μ M for 95D medium effective concentration (EC50).Ganoderic acid Me GA-Me (+)-Ganoderic acid Me is 40 μ M for 95D medium effective concentration (EC50).These two concentration all surpass the IC50 of medicine for 95D, and as seen, Ganodenic acid is the locomotivity of anticancer targetedly, but and this effect be dose dependent.
Ganoderic acid T GA-T Ganoderic acid T. and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me stick the inhibition test of ability to cancerous cell
Matrigel (artificial Matrigel), LN, FN are laid in the 96 porocyte culture plates, add tumor cell then, after hatching through certain hour, rinse out not adherent cell.Adhering to the light absorption value that the cell quantity on the plate measures with the MTT method reflects.
As can be seen from Figure 3, along with the increase of Ganodenic acid concentration, adherent cells ratio reduces, and illustrates that Ganodenic acid can effectively suppress the ability of tumor cell adhesion to the basement membrane.Ganoderic acid T GA-T Ganoderic acid T. is respectively 12.6 μ M for the medium effective concentration (EC50) of 95D, and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me is 50 μ M for 95D medium effective concentration (EC50).Two kinds of compositions can both effectively suppress the adhesive capacity of tumor cell, and wherein Ganoderic acid T GA-T Ganoderic acid T. is more more obvious than the effect of Ganoderic acid Me GA-Me (+)-Ganoderic acid Me.
The external inhibition of Ganoderic acid T GA-T Ganoderic acid T. and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me to the neoplasm metastasis ability
By the foundation of Lewis lung cancer animal model, observe inhibition and the anticancer transcellular effect of Ganodenic acid to the tumor animal tumor.
Aseptic extraction tumor from Lewis lung cancer kind Mus, aseptic condition inoculation mice.Mice be 6 the week age C57BL/6, male, in SPF Animal House ad lib and drinking-water.
Postvaccinal mice is divided into 6 groups at random:
The tumor matched group is pressed a normal saline 0.5ml/ gastric infusion, 3 in the Figure 4 and 5;
Positive drug cisplatin group (1mg/kg), 4 in the Figure 4 and 5;
Ganoderic acid Me GA-Me (+)-Ganoderic acid Me low dose group (7mg/kg), 5 in the Figure 4 and 5,
Ganoderic acid Me GA-Me (+)-Ganoderic acid Me high dose group (28mg/kg), 6 in the Figure 4 and 5;
Ganoderic acid T GA-T Ganoderic acid T. low dose group (7mg/kg), 7 in the Figure 4 and 5;
Ganoderic acid T GA-T Ganoderic acid T. high dose group (28mg/kg), 8 in the Figure 4 and 5;
Inoculate administration in back 72 hours.First and second day of medication is carried out lumbar injection 0.1ml to positive drug cisplatin group (1mg/kg), and all the other Ganodenic acid treated animals carry out gastric infusion, once a day, and continuous 10 days.Put to death animal on the 20th day, win tumor, the weighing tumor is heavy, fixing lung tissue, the anatomic microscope lung metastatic nodules that counts down.The result is with means standard deviation (x ± s) expression; Significance of difference paired t-test.Compare with matched group,
*P＜0.05,
*P＜0.01.
As can be seen from Figure 4, respectively in Ganoderic acid Me GA-Me (+)-Ganoderic acid Me and Ganoderic acid T GA-T Ganoderic acid T. group, the inhibition of tumor is increased along with the increase of Ganodenic acid concentration, and Ganoderic acid Me GA-Me (+)-Ganoderic acid Me high dose and T high dose group and tumor matched group have significant difference (p＜0.05).Calculate tumor control rate according to formula: inhibition rate of tumor growth=[(the average tumor of the average tumor weight-medicine of matched group group is heavy)/average tumor of matched group is heavy] * 100%.The result shows that Ganoderic acid Me GA-Me (+)-Ganoderic acid Me high dose and T high dose group are respectively 43.23% and 58.91% for the heavy suppression ratio of tumor.The above results shows that Ganoderic acid Me GA-Me (+)-Ganoderic acid Me and Ganoderic acid T GA-T Ganoderic acid T. can suppress growth of tumor.
As seen from Figure 5, compare with matched group, Ganoderic acid Me GA-Me (+)-Ganoderic acid Me high dose group and Ganoderic acid T GA-T Ganoderic acid T. high dose group have significant difference.Calculate the metastasis inhibition rate according to formula: metastasis inhibition rate=(the matched group lung shifts number-medicine group lung and shifts number)/matched group lung shifts number * 100%.After mice was taken the Ganoderic acid T GA-T Ganoderic acid T. high dose, the metastasis rate reached 73.68%.The metastasis suppression ratio of Ganoderic acid Me GA-Me (+)-Ganoderic acid Me high dose group is 54.89%.Illustrate that Ganoderic acid T GA-T Ganoderic acid T. can effectively suppress the spontaneous transfer of Lewis lung cancer mice, effect is comparatively obvious.
Illustrate that Ganoderic acid T GA-T Ganoderic acid T. and Me can suppress growth of tumor, and can suppress the spontaneous transfer of Lewis lung cancer mice.
With GA-Me or GA-T and 199 parts of distilled water mix homogeneously of 1 weight portion, packing promptly obtains oral liquid.
With the GA-Me of 1 weight portion or the injection normal saline mix homogeneously of GA-T and 199 weight portions, promptly obtain injection.
Adopt quick colorimetric method for determining GA-Me of tetrazolium bromide (MTT) and GA-T to KB, the toxic action of HeLa and 95-D tumor cell and HLF human normal cell line.Various cells (10 with exponential phase
6Cellml
-1) being inoculated in 96 well culture plates, every hole 0.2ml adds 50,100,150 and 200 μ g ml respectively
-1The GA-Me of concentration and GA-T handle, parallel 4 holes of every concentration, and matched group adds the culture fluid of equivalent volumes, puts 37 ℃, 5%CO
2And the incubator of saturated humidity was cultivated preceding 4 hours every hole adding 5mgml of experiment termination 1-4 days
-1MTT 10 μ l, cultivate and finish the every hole adding in back 0.04N dimethyl sulfoxide (DMSO), every hole 150 μ l, vibration 10min treats that the MTT reduzate dissolves fully, with BioRad 550 type microplate reader, with 550nm is the experiment wavelength, 655nm is for to measure its trap with reference to wavelength, calculates the suppression ratio of medicine pair cell, and with the half-inhibition concentration (IC of cell
50) mapping.The result of statistical experiment data as shown in Figure 6.
Above embodiment explanation, GA-Me and GA-T are all less to the toxicity of human normal cell's strain.
Claims (4)
1. the application of Ganodenic acid in the preparation cancer transfer inhibitor, said Ganodenic acid is Ganoderic acid Me GA-Me (+)-Ganoderic acid Me or Ganoderic acid T GA-T Ganoderic acid T..
2. application according to claim 1 is characterized in that said tumor comprises benign tumor or malignant tumor.
3. application according to claim 2, it is characterized in that, and said malignant tumor comprises: malignant melanoma, malignant lymphoma, Alimentary tumor, pulmonary carcinoma, breast carcinoma, carcinoma of testis, ovarian cancer, uterus carcinoma, carcinoma of prostate, maxillary cancer, carcinoma of tongue, oral cancer, laryngocarcinoma, thyroid carcinoma, brain tumor, each sarcoid, osteosarcoma, leukemia, nervous system neoplasms, tumor of bladder, skin carcinoma, skin accessory organ's cancer or metastatic carcinoma of skin.
4. a complex comprises right 1 described Ganoderic acid Me GA-Me (+)-Ganoderic acid Me or the Ganoderic acid T GA-T Ganoderic acid T. and the pharmaceutically acceptable carrier for the treatment of effective dose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510112303 CN1823787A (en) | 2005-12-29 | 2005-12-29 | Application of lucid ganoderma acid in preparation of cancer transfer inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510112303 CN1823787A (en) | 2005-12-29 | 2005-12-29 | Application of lucid ganoderma acid in preparation of cancer transfer inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1823787A true CN1823787A (en) | 2006-08-30 |
Family
ID=36934729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510112303 Pending CN1823787A (en) | 2005-12-29 | 2005-12-29 | Application of lucid ganoderma acid in preparation of cancer transfer inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1823787A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101623502B (en) * | 2009-05-08 | 2011-06-08 | 华东理工大学 | Preparation method of Ganodenic acid monomer Me cyclodextrin inclusion compound and of oral solid preparation |
| CN104173354A (en) * | 2013-05-28 | 2014-12-03 | 双鹤生物科技股份有限公司 | Pharmaceutical composition able to treat cancer |
| CN106421795A (en) * | 2012-10-08 | 2017-02-22 | 贾力 | Medicinal composition for preventing re-metastasis of primary tumor after excision |
| CN114053285A (en) * | 2021-09-07 | 2022-02-18 | 中国医学科学院药用植物研究所 | Application of ganoderic acid X in treating tumor |
| CN117298124A (en) * | 2023-11-28 | 2023-12-29 | 中国中医科学院中药研究所 | Application of ganoderic acid T in preparation of medicine for treating allergic asthma |
-
2005
- 2005-12-29 CN CN 200510112303 patent/CN1823787A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101623502B (en) * | 2009-05-08 | 2011-06-08 | 华东理工大学 | Preparation method of Ganodenic acid monomer Me cyclodextrin inclusion compound and of oral solid preparation |
| CN106421795A (en) * | 2012-10-08 | 2017-02-22 | 贾力 | Medicinal composition for preventing re-metastasis of primary tumor after excision |
| CN104173354A (en) * | 2013-05-28 | 2014-12-03 | 双鹤生物科技股份有限公司 | Pharmaceutical composition able to treat cancer |
| CN104173354B (en) * | 2013-05-28 | 2017-12-12 | 双鹤生物科技股份有限公司 | Can treating cancer pharmaceutical compositions |
| CN114053285A (en) * | 2021-09-07 | 2022-02-18 | 中国医学科学院药用植物研究所 | Application of ganoderic acid X in treating tumor |
| CN117298124A (en) * | 2023-11-28 | 2023-12-29 | 中国中医科学院中药研究所 | Application of ganoderic acid T in preparation of medicine for treating allergic asthma |
| CN117298124B (en) * | 2023-11-28 | 2024-02-09 | 中国中医科学院中药研究所 | Application of ganoderic acid T in preparation of medicine for treating allergic asthma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
| CN1891240A (en) | Chinese medicine composition containing multi glossy ganoderma active constituents and its preparing method | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN1823787A (en) | Application of lucid ganoderma acid in preparation of cancer transfer inhibitor | |
| CN101057872A (en) | Anti tumor active part of American cockroach prepared with reverse phase material and medical application | |
| CN107488162A (en) | A kind of bicyclic alcohol derivatives and its preparation and application | |
| CN102731276A (en) | Diterpene compound possessing antitumor activity, preparation method thereof and application thereof | |
| KR100310121B1 (en) | Treatment of tumor diseases using thiazopurine and ribavirin | |
| CN111228287A (en) | Application of epimedium flavone glycoside compound in preparing medicine for treating melanoma | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN100408042C (en) | Use of ganoderic acid T and ganoderic and Me in tumour growth or proliferation inhibitor | |
| CN101084905B (en) | Application of ganoderic acid Me in tumoral growth or propagation inhibitor | |
| CN102441000B (en) | Anti-cancer anti-disease buccal tablet | |
| CN105399794A (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
| CN102688248A (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN1305479C (en) | Low polarity ginsenoside combination possessing anti-tumor activity | |
| CN1871227A (en) | Antitumoral agent | |
| CN1557416A (en) | Medicine preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1559392A (en) | Applicaton of gallic acid in prepn. of medicine for antitumor | |
| CN105030798B (en) | A kind of antitumor medicine composition and its preparation method and application | |
| CN104147036B (en) | Decitabine and oxaliplatin are applied in treatment renal cell carcinoma composition of medicine is prepared | |
| CN105085221B (en) | Compound with antifungal and anti-tumor activity and preparation method and application | |
| CN110123825B (en) | Pharmaceutical composition containing demethoxydaunorubicin | |
| CN103724177B (en) | Compound with antifungal activity and preparation method and application thereof | |
| CN102440994A (en) | Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |